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Abstract
Background. Peripheral low-grade inflammation in depression is increasingly seen as a thera-
peutic target. We aimed to establish the prevalence of low-grade inflammation in depression,
using different C-reactive protein (CRP) levels, through a systematic literature review and
meta-analysis.
Methods. We searched the PubMed database from its inception to July 2018, and selected
studies that assessed depression using a validated tool/scale, and allowed the calculation of
the proportion of patients with low-grade inflammation (CRP >3 mg/L) or elevated CRP
(>1 mg/L).
Results. After quality assessment, 37 studies comprising 13 541 depressed patients and
155 728 controls were included. Based on the meta-analysis of 30 studies, the prevalence of
low-grade inflammation (CRP >3 mg/L) in depression was 27% (95% CI 21–34%); this preva-
lence was not associated with sample source (inpatient, outpatient or population-based), anti-
depressant treatment, participant age, BMI or ethnicity. Based on the meta-analysis of 17
studies of depression and matched healthy controls, the odds ratio for low-grade inflammation
in depression was 1.46 (95% CI 1.22–1.75). The prevalence of elevated CRP (>1 mg/L) in
depression was 58% (95% CI 47–69%), and the meta-analytic odds ratio for elevated CRP
in depression compared with controls was 1.47 (95% CI 1.18–1.82).
Conclusions. About a quarter of patients with depression show evidence of low-grade inflam-
mation, and over half of patients show mildly elevated CRP levels. There are significant dif-
ferences in the prevalence of low-grade inflammation between patients and matched healthy
controls. These findings suggest that inflammation could be relevant to a large number of
patients with depression.
Introduction
Depression is a common mental illness with a complex aetiology and is one of the leading
causes of disability worldwide, affecting around 10–20% of the general population in their life-
time (Lim et al., 2018). There is now increasing evidence suggesting an association between
depression and inflammation (Goldsmith et al., 2016). For instance, ‘sickness behaviour’ com-
monly seen following an acute infection, shares many characteristics with depression, such as
fatigue, sleep disturbance and decreased motivation (Dantzer et al., 2008); early-life infection
and autoimmune diseases are associated with a higher risk of depression in adulthood (Benros
et al., 2013); people with chronic immune-mediated inflammatory diseases such as rheuma-
toid arthritis exhibit a higher prevalence of depression (Dickens et al., 2002). Depression is
also associated with other conditions linked with elevated inflammatory markers, such as car-
diovascular disease (CVD) (Ridker, 2003).
C-reactive protein (CRP) is a marker of acute phase response which has been used most
extensively as a measure of low-grade inflammation in psychiatric (von Känel et al., 2007;
Fernandes et al., 2016) and physical conditions (Visser et al., 1999; Danesh et al., 2000).
CRP is associated with cardiovascular risk, including myocardial infarction, stroke, sudden
cardiovascular death and peripheral vascular disease (Ridker, 2003). Meta-analyses of cross-
sectional studies confirm that mean concentrations of circulating CRP and inflammatory cyto-
kines such as interleukin 6 (IL-6) are higher in patients with acute depression compared with
controls (Howren et al., 2009; Dowlati et al., 2010; Haapakoski et al., 2015; Goldsmith et al.,
2016). Population-based longitudinal studies show that higher levels of CRP and IL-6 at base-
line are associated with an increased risk of depression in subsequent follow-ups (Gimeno
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et al., 2009; Wium-Andersen et al., 2013; Khandaker et al., 2014;
Zalli et al., 2016), suggesting that inflammation could be a cause
rather than simply a consequence of the illness.
The association between inflammation and depression is clin-
ically relevant. Poor response to antidepressants is associated with
the activation of inflammatory immune responses (Lanquillon
et al., 2000; Benedetti et al., 2002; Carvalho et al., 2013;
Chamberlain et al., 2018). It has been reported the mean CRP
levels are higher in treatment-resistant compared with treat-
ment-responsive patients with depression (Maes et al., 1997;
Sluzewska et al., 1997). Anti-inflammatory treatment has anti-
depressant effects (Müller et al., 2006; Köhler et al., 2014;
Kappelmann et al., 2018). Randomised controlled trials (RCTs)
indicate that anti-inflammatory drugs are likely to be beneficial
particularly for depressed patients who show evidence of inflam-
mation (Raison et al., 2013; Kappelmann et al., 2018). Currently, a
number of ongoing RCTs of anti-inflammatory treatments are
recruiting specifically depressed patients with elevated CRP levels
(e.g. ⩾3 mg/L): NCT02473289; ISRCTN16942542 (Khandaker
et al., 2018). Therefore, a better understanding of the prevalence
of low-grade inflammation in depression, and of factors asso-
ciated with inflammation could inform future research and clin-
ical practice.
Inflammation is unlikely to be relevant for all patients with
depression (Khandaker et al., 2017). While it is established that
mean concentrations of peripheral inflammatory markers are
higher in depressed patients compared with controls (Howren
et al., 2009; Dowlati et al., 2010; Haapakoski et al., 2015;
Goldsmith et al., 2016), it is unclear what proportion of depressed
patients show evidence of low-grade inflammation. Many studies
have reported on the prevalence of inflammation in depressed
patients using various CRP level thresholds to define inflamma-
tion, e.g. >3 or >1 mg/L. These studies have been conducted in
different settings and populations, e.g. inpatient, outpatient,
population-based (Raison et al., 2013; Wium-Andersen et al.,
2013; Shin et al., 2016). The reported prevalence of inflammation
varies widely among these studies; for example, for low-grade
inflammation (CRP >3 mg/L) it has been reported to vary
between 0% and 60% in existing studies (Ma et al., 2011;
Hannestad et al., 2013). However, as far as we are aware, a system-
atic review and meta-analysis of the prevalence of low-grade
inflammation in patients with depression is currently lacking.
While it is likely that the prevalence of low-grade inflammation
is higher in patients with depression compared with controls, to
our knowledge, no systematic review and meta-analysis has exam-
ined the odds ratio for inflammation in depressed patients com-
pared with matched controls.
We conducted a systematic review of existing studies to: (1)
quantify the prevalence of low-grade inflammation in patients
with depression using meta-analysis; (2) calculate the odds ratio
for low-grade inflammation in depressed patients compared
with matched healthy controls using meta-analysis; (3) identify
sociodemographic and other factors associated with inflammation
prevalence in patients with depression using meta-regression ana-
lysis. We defined low-grade inflammation as serum CRP levels
>3 mg/L. This cut-off has been chosen based on the American
Heart Association and Center for Disease Control and
Prevention recommendations, which defined CRP levels of
>3 mg/L as high (Pearson et al., 2003). In addition, we carried
out additional analyses using CRP levels >1 mg/L to define ‘ele-
vated CRP’, and >10 mg/L to define ‘very high CRP’ indicative
of current infection. We also carried out a number of sensitivity
analyses; for example, meta-analyses using >1 and >3 mg/L
thresholds for CRP were repeated using only studies that excluded
patients with suspected infection (defined as CRP >10 mg/L); and
after excluding poor quality studies.
Methods
Search strategy and study selection
This systematic review has been performed according to the
Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) guidelines. The search protocol was prospect-
ively published on PROSPERO (see: http://www.crd.york.ac.
uk/PROSPERO/display_record.asp?ID=CRD42018106640). The
PubMed database was searched for published studies from its
inception to 5 of July 2018 using the following keywords: ‘(CRP
OR “C-reactive protein” OR “hs-CRP” OR hsCRP) OR
(C-Reactive Protein[mesh] AND depressi*)’. No language restric-
tion was applied; we only selected studies based on human
participants. The electronic search was complemented by hand-
searching of meta-analyses and review articles. Abstracts were
screened, and full texts of relevant studies were retrieved. Two
authors applied the inclusion/exclusion criteria independently
and selected the final studies for this review (LB and EFO).
Selection criteria
We included studies that: (1) examined CRP levels in people with
depression; (2) assessed depression using clinical criteria (DSM or
ICD) or a validated tool (e.g. Hamilton Depression Rating Scale),
and reported it as a categorical variable (yes/no); (3) reported
CRP levels allowing the calculation of the proportion of ‘inflamed’
patients using cut-offs of either 3, 1 or 10 mg/L. One study used
CRP cut-offs of 0.99 and 3.13 mg/L, which was included (Penninx
et al., 2003), as these values are very close to the thresholds above.
Exclusion criteria were (1) studies reporting measures of inflam-
mation other than CRP, e.g. interleukins or genetic markers; (2)
in vitro or animal studies; (3) non-original data, e.g. reviews; (4)
studies exclusively based on patients with a medical condition,
e.g. cancer.
Recorded variables
The main outcome measure was the proportion of subjects show-
ing elevated CRP in patients and, where reported, in non-
depressed controls. We also extracted the following data: author;
year of publication; sampling criteria; diagnostic criteria for
depression; age of participants; treatment status (antidepressant-
free, treatment resistant); ethnicity; matching criteria for patients
and controls (if present); study setting and sample source (e.g.
community or inpatient); presence of comorbidities. If there
were multiple publications from the same data set, we used the
study with the largest sample.
Data synthesis
We performed meta-analyses of the prevalence of inflammation
in depressed patients using three different CRP cut-offs to define
inflammation: >3 (primary), >1 and >10 mg/L. The pooled preva-
lence of inflammation was calculated using quantitative
random-effect meta-analysis, expressed as percentage and 95%
CI. The use of random-effect meta-analysis, as opposed to fixed
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effect, is appropriate when there is heterogeneity between studies.
Pooling of studies was performed using the inverse variance
method, so that studies with bigger samples were given greater
weight. The Clopper–Pearson method was used to compute con-
fidence interval for individual studies, and the logit transform-
ation was used for the transformations of proportions, with a
continuity correction of 0.5 in studies with zero cell frequencies.
Heterogeneity between studies was measured using the I2 statistic,
which describes the percentage of the variability in effect esti-
mates that is due to heterogeneity. Heterogeneity was tested
using Cochrane’s Q-Test (Higgins and Thompson, 2002).
Publication bias was assessed for each group of studies by visual
inspection of funnel plots, and tested with an Egger’s regression
test for funnel plot asymmetry (mixed-effects meta-regression
model). P values <0.05, two tailed, were considered statistically
significant. We used meta-regression analyses to evaluate the
association of inflammation prevalence with age, sex, body mass
index (BMI), sample source, proportion of antidepressant-free
patients and ethnicity. Seventeen studies reported CRP levels in
matched non-depressed controls; these were used to calculate
the meta-analytic odds ratio for inflammation in patients with
depression v. healthy controls using random-effects estimates
for meta-analyses with binary outcome data; pooling of studies
was performed using the inverse variance method and with a con-
tinuity correction of 0.5 in studies with zero cell frequencies.
Study quality was assessed using the Newcastle–Ottawa Scale
(Stang, 2010). Analyses were repeated with poor quality studies
removed. Meta-analyses were carried out using the meta package
[version 4.9 (Schwarzer, 2007)] in R 3.4 (R Core Team, 2017), and
plotted using packages meta and Cairo v1.5 (Urbanek and
Horner, 2015). Additional information on the methods can be
found in the Supplementary Materials.
Results
The literature search yielded 1545 results, out of which 37 studies
met the inclusion criteria for meta-analysis (Legros et al., 1985;
Penninx et al., 2003; Ladwig et al., 2005; Liukkonen et al., 2006;
O’brien et al., 2006; Almeida et al., 2007; Kling et al., 2007;
Danese et al., 2008; Nilsson et al., 2008; Cizza et al., 2009;
Harley et al., 2010; Ma et al., 2011; Naghashpour et al., 2011;
Hannestad et al., 2013; Raison et al., 2013; Shanahan et al.,
2013; Park et al., 2014; Uher et al., 2014; Wium-Andersen
et al., 2014; Courtet et al., 2015; Wysokiński et al., 2015;
Cepeda et al., 2016; Haroon et al., 2016; Rapaport et al., 2016;
Shin et al., 2016; Ekinci and Ekinci, 2017; Euteneuer et al.,
2017; Gallagher et al., 2017; Horsdal et al., 2017; Jha et al.,
2017; Cáceda et al., 2018; Chamberlain et al., 2018; Felger et al.,
2018; Osimo et al., 2018b; Porcu et al., 2018; Shibata et al.,
2018; Wei et al., 2018). Please see Supplementary Fig. S1 for
the PRISMA diagram of study selection, and Table 1 for details
of the included studies.
Prevalence of low-grade inflammation (CRP >3 mg/L) in
depressed patients
Results based on all available studies
Thirty studies comprising 11 813 patients with depression were
used for this analysis. The meta-analytic pooled prevalence of
low-grade inflammation in depressed patients was 27% (95% CI
21–34%); see Fig. 1. There was evidence of heterogeneity among
studies (I2 = 97.7%; 95% CI 97.3–98.1%; Cochrane’s Q = 1264;
p = <0.01). Further analyses after grouping studies by setting
showed that the prevalence of inflammation in inpatient samples
(N = 1265) was 30% (95% CI 21–42%; I2 = 91.9%; Cochrane’s Q =
62); in outpatient samples (N = 3528) it was 29% (95% CI 19–43%;
I2 = 95.9%; Cochrane’s Q = 338); and in population-based samples
(N = 7020) it was 24% (95% CI 17–34%; I2 = 98.3%; Cochrane’s
Q = 483).
Analyses excluding poor quality studies or cases with past
depression
A sensitivity analysis excluding six poor quality studies, compris-
ing 8778 patients, showed that the prevalence of inflammation
was 27% (95% CI 22–33%); Supplementary Table S1 and
Fig. S2. There was evidence of heterogeneity (I2 = 96.4%; 95%
CI 95.5–97.1%; Cochrane’s Q = 644; p = <0.01). A sensitivity ana-
lysis excluding two studies where depression was not active in all
patients, comprising 11 763 patients, showed that the prevalence
of inflammation was 26% (95% CI 20–34%); Supplementary
Fig. S3. There was evidence of heterogeneity (I2 = 97.9%; 95%
CI 97.4–98.2%; Cochrane’s Q = 1261; p = <0.01).
Analysis after excluding cases of suspected infection
(CRP >10 mg/L)
Nine studies reported the prevalence of low-grade inflammation
after excluding participants with suspected infection, defined as
CRP >10 mg/L. A separate meta-analysis based on these studies,
comprising 6948 patients, showed that the prevalence of inflam-
mation was 16% (95% CI 8–32%); Supplementary Fig. S4.
There was evidence of heterogeneity (I2 = 98.8%; 95% CI 98.5–
99.1%; Cochrane’s Q = 675; p = <0.01).
Association between prevalence of low-grade inflammation
(CRP >3 mg/L) and characteristics of depressed patients
Meta-regression was used on 19 studies comprising 7858 patients
to test the association between the prevalence of inflammation
and the proportion of patients who were antidepressant-free at
the time of study. There was no association between these factors
(estimate: −0.007; z = −1.03; p = 0.30). Similarly, sex, age,
non-White ethnicity, BMI and sample source (inpatient, out-
patient or population-based) were not associated with the preva-
lence of inflammation (see Supplementary Results).
Assessment of publication bias
A funnel plot of the 30 studies assessing the prevalence of low-
grade inflammation (CRP >3 mg/L) in depression visually
appeared symmetrical (Supplementary Fig. S5). Egger’s regression
test for funnel plot asymmetry was non-significant (t =−1.3; df =
28; p = 0.21), suggesting there was no evidence of publication bias.
Odds ratio for low-grade inflammation (>3 mg/L) in depressed
patients
Seventeen studies reported the prevalence of inflammation in
7761 depressed patients and 155 728 matched non-depressed con-
trols (see Supplementary Table S2 for matching details). The
meta-analytic OR for inflammation in depressed patients com-
pared with matched controls was 1.46 (95% CI 1.22–1.75; p <
0.0001); see Fig. 2. There was evidence of heterogeneity (I2 =
71.9%; 95% CI 54.3–82.7%; Cochrane’s Q = 57; p = <0.01).
Based on the same studies, we meta-analysed the prevalence of
inflammation in depressed patients and matched non-depressed
controls separately. The prevalence of inflammation in controls
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Table 1. Characteristics of studies included in the meta-analysis
Study Country Setting
Depressed
(N)
Controls
(N)
Mean age of patients in years
(SD)
Patient
sex (%
male) Assessment of depressiona
Quality
ratingb
Legros et al.
(1985)
Belgium Inpatient 34 NAc 42 (NA) NA Feighner et al. (1972) criteria
(Feighner et al., 1972)
Good
Penninx et al.
(2003)
USA Prospective
/population-based
145 2879 74 (2.9) 38.62 CES-D Good
Ladwig et al.
(2005)
Germany Prospective
/population-based
986 2035 57.5 (7.8) 100 Subscale from the von Zerssen
affective symptom checklist
(von Zerssen and Cording,
1978); depression = score ⩾11
Good
Liukkonen et al.
(2006)
Finland Prospective
/population-based
962 4097 31 (0) 39.4 Hopkins symptom checklist-25
(Parloff et al., 1954)
Good
O’Brien et al.
(2006)
Ireland Outpatient 32 20 44.05 (NA) 34.38 DSM-IV Poor
Almeida et al.
(2007)
Australia Prospective
/population-based
213 4000 76.6 (4.4) 100 GDS-15 score ⩾7 Good
Kling et al. (2007) USA and Israel Outpatient 18 18 41 (12) 0 DSM-IV Good
Danese et al.
(2008)
UK Prospective
/population-based
109 673 32 (0) 39.45 DSM-IV Good
Nilsson et al.
(2008)
Sweden Outpatient 50 NA Median age 71 years NA DSM IV Good
Cizza et al. (2009) USA Outpatient 77 41 35.5 (7) 0 DSM-IV SCI Good
Harley et al.
(2010)
New Zealand Outpatient 346 NA NA NA DSM-IV SCI, Montgomery Asberg
Depression Rating Scale
Poor
Ma et al. (2011) USA Outpatient 10 498 NA 30 BDI score ⩾22 Poor
Naghashpour
et al. (2011)
Iran Outpatient 43 52 37.26 (6.5) 0 BDI score >5 Poor
Hannestad et al.
(2013)
USA Outpatient 9 7 37 (14.3) 44.44 DSM-IV Fair
Raison et al.
(2013)
USA Outpatient 60 NA 43.4 (8.8) 33.33 DSM-IV depression through
SCID
Good
Shanahan et al.
(2013)
USA Prospective
/population-based
61 NA 13.5 (1.9) NA DSM-IV criteria assessed
through CAPA
Good
Park et al. (2014) Korea Outpatient 30 30 65.2 (4.8) 30 DSM-IV SCI Good
Uher et al. (2014) Canada, UK,
Germany,
Croatia,
Denmark,
Slovenia,
Belgium
Outpatient 241 NA 40.7 (11.4) 37.34 Schedule for Clinical
Assessment in Neuropsychiatry
Good
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Wium-Andersen
et al. (2014)
Denmark Prospective
/population-based
1183 77 626 65 (NA) 36.35 ICD criteria Poor
Wysokiński et al.
(2015)
Poland Inpatient 319 NA 59.7 (21) 23.82 ICD-10 Poor
Courtet et al.
(2015)
France Inpatient 600 NA 39.8 (13.4) 27.83 DSM-IV Good
Cepeda et al.
(2016)
USA Prospective
/population-based
1325 12 951 45.3 (12) 35.92 PHQ9 score >9 Good
Haroon et al.
(2016)
USA Outpatient 50 NA 38.6 (10.8) 32 DSM-IV Fair
Rapaport et al.
(2016)
USA Outpatient 155 NA 46.1(12.6) 41.29 DSM-IV SCID, Clinical global
impressions severity score,
HAMD-17
Fair
Shin et al. (2016) Korea Outpatient 2492 49 736 36.75 (6.52) 66.77 CES-D score ⩾21 Poor
Ekinci and Ekinci
(2017)
Turkey Inpatient 139 50 42.2 (12.3) 30.21 DSM-IV Poor
Euteneuer et al.
(2017)
Germany Outpatient 98 30 37.3 (12.2) 51.02 DSM-IV Good
Gallagher et al.
(2017)
Canada Prospective
/population-based
811 5084 67.3 (10.8) 32.18 CES-D ⩾4 Poor
Horsdal et al.
(2017)
Denmark Prospective
/population-based
2187 NA Median age 35.7 years 37.4 ICD-8 and ICD-10 Good
Jha et al. (2017) USA, Singapore Outpatient 106 NA 46.64 (11.89) 30.19 International Neuropsychiatric
Interview (MINI)
Good
Wei et al. (2018) China Inpatient 18 15 43.89 (20.78) 27.78 DSM-IV Good
Cáceda et al.
(2018)
USA Inpatient 52 NA 36.8 (12.6) 36.54 DSM-IV Good
Chamberlain
et al. (2018)
UK Outpatient 198 54 36.5 (NA) 15.15 DSM-5 Good
Felger et al. (2018) USA Outpatient 73 NA 42.1 (11.1) 42.47 SCID-IV Good
Osimo et al.
(2018b)
UK Inpatient 137 NA 40(13) 47.44 ICD-10 Good
Porcu et al. (2018) Brazil Outpatient 67 NA 46 (NA) NA DSM-5, ICD-10 Good
Shibata et al.
(2018)
Japan Prospective
/population-based
105 2424 65.5 (11.1) NA CESD score ⩾16 Poor
aCES-D, The Center for Epidemiologic Studies Depression Scale; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition; GDS, Geriatric Depression Scale; BDI, Beck’s Depression Inventory; SCID, Structured Clinical Interview for DSM;
CAPA, The Child and Adolescent Psychiatric Assessment; ICD, World Health Organisation International Classification of Diseases; PHQ9, Patient Health Questionnaire-9; HAMD-17, Hamilton Depression Rating Scale (HDRS).
bStudies evaluated using the Newcastle–Ottawa Scale (see Supplementary methods and Table S1), then converted to Agency for Healthcare Research and Quality – AHRQ – standards (good, fair and poor) using these thresholds:
• Good quality: ⩾75% in Selection domain AND ⩾50% in Comparability domain AND ⩾50% in Outcome domain.
• Fair quality: 50% in Selection domain AND ⩾50% in Comparability domain AND ⩾50% in Outcome domain.
• Poor quality: ⩽50% in Selection domain OR 0% in Comparability domain OR ⩽50% in Outcome domain.
cNot available.
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was 16% (95% CI 11–23%) and that in depressed patients was
24% (95% CI 17–34%); see Supplementary Figs S6 and S7.
We carried out sensitivity analyses based on five available stud-
ies of depressed patients and matched healthy controls that
excluded subjects with very high levels of CRP (>10 mg/L).
These studies, comprising 3868 patients and 63 212 controls,
showed that the prevalence of inflammation in controls was
10% (95% CI 3–26%) and that in patients it was 13% (95% CI
4–36%); see Supplementary Figs S8 and S9. Based on these stud-
ies, the meta-analytic OR for inflammation in depressed patients
compared with matched controls was 1.44 (95% CI 0.80–2.61; p =
0.23); see Supplementary Fig. S10.
A sensitivity analysis excluding poor quality studies, compris-
ing 5045 patients and 105 372 controls, showed that the
Fig. 1. Prevalence of low-grade inflammation (CRP >3 mg/L) in depressed patients.
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meta-analytic OR for inflammation in depressed patients com-
pared with matched controls was 1.56 (95% CI 1.29–1.88; p <
0.0001); see Supplementary Table S1 and Fig. S11. A further sen-
sitivity analysis only including studies that matched patients and
controls by BMI, comprising 2624 patients and 79 887 controls,
showed that the meta-analytic OR for inflammation in depressed
patients compared with matched controls was 1.59 (95% CI 1.08–
2.34; p = 0.02); see Supplementary Fig. S12. Finally, a sensitivity
analysis excluding studies where depression was not active in all
patients showed that the meta-analytic OR for inflammation in
depressed patients compared with matched controls was 1.47
(95% CI 1.22–1.75; p = 0.02); see Supplementary Fig. S13.
Prevalence of elevated CRP levels (>1 mg/L) in depressed
patients
Results based on all available studies
Twenty-five studies comprising 8887 patients with depression
were used for this analysis. The meta-analytic pooled prevalence
of elevated CRP >1 mg/L in depressed patients was 58% (95%
CI 47–69%); see Fig. 3. There was evidence of heterogeneity
(I2 = 98.7%; 95% CI 98.5–98.9%; Cochrane’s Q = 1862; p =
<0.01). Further analyses after grouping studies by setting showed
that the prevalence of elevated CRP in inpatient samples (N =
1023) was 56% (95% CI 46–66%; I2 = 81.8%; Cochrane’s Q =
22); in outpatient samples (N = 697) was 59% (95% CI 50–67%;
I2 = 74.9%; Cochrane’s Q = 40); and in population-based
samples (N = 7167) was 57% (95% CI 34–77%; I2 = 99.5%;
Cochrane’s Q = 1774).
Analyses excluding poor quality studies or cases with past
depression
A sensitivity analysis excluding four poor quality studies showed
that the prevalence of elevated CRP >1 mg/L in depressed patients
was 57% (95% CI 43–69%); Supplementary Table S1 and Fig. S14.
There was evidence of heterogeneity (I2 = 98.9%; 95% CI 98.7–
99.1%; Cochrane’s Q = 1858; p = <0.01). A further sensitivity ana-
lysis excluding studies where depression was not active in all
patients showed that the prevalence of elevated CRP in depressed
patients was 58% (95% CI 45–69%); Supplementary Fig. S15.
There was evidence of heterogeneity (I2 = 98.8%; 95% CI 98.6–
99.0%; Cochrane’s Q = 1861; p = <0.01).
Analysis after excluding cases of suspected infection
(CRP>10 mg/L)
Eight studies also reported the prevalence of elevated CRP after
excluding participants with suspected infection, defined as CRP
>10 mg/L. A separate meta-analysis based on these studies, com-
prising 4456 patients that excluded patients with CRP levels
>10 mg/L showed that the prevalence of elevated CRP >1 mg/L
was 50% (95% CI 29–72%); see Supplementary Fig. S16 There
was evidence of heterogeneity (I2 = 99.1%; 95% CI 98.9–99.3%;
Cochrane’s Q = 816; p = <0.01).
Association between prevalence of elevated CRP levels (>1 mg/L)
and characteristics of depressed patients
Meta-regression analyses did not find any significant association
of elevated CRP with sex, age, BMI, non-White ethnicity, being
antidepressant-free or sample source (see Supplementary Results).
Fig. 2. Odds ratio for low-grade inflammation (CRP >3 mg/L) in depressed patients compared with matched controls.
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Assessment of publication bias
A funnel plot of the 25 studies assessing the prevalence of elevated
CRP in depression appeared visually symmetrical. Egger’s regres-
sion test for funnel plot asymmetry was non-significant (t =
−0.43; df = 23; p = 0.67), suggesting there was no evidence of pub-
lication bias (Supplementary Fig. S17).
Odds ratio for elevated CRP levels (>1 mg/L) in depressed
patients
Fifteen studies reported the prevalence of elevated CRP >1 mg/L
in 5177 depressed patients and 106 682 matched non-depressed
controls (see Supplementary Table S2 for matching details). The
meta-analytic OR for elevated CRP in depressed patients
compared with matched controls was 1.47 (95% CI 1.18–1.82;
p = 0.0005); see Fig. 4. There was evidence of heterogeneity
(I2 = 75.6%; 95% CI 59.8–85.2%; Cochrane’s Q = 57; p = <0.01).
Based on the same studies, we meta-analysed the prevalence of
elevated CRP in depressed patients and matched non-depressed
controls separately. The prevalence of elevated CRP >1 mg/L in
controls was 44% (95% CI 26–65%) and that in depressed patients
was 59% (95% CI 41–75%); see Supplementary Figs S18 and S19.
A sensitivity analysis based on 12 studies after excluding poor
quality studies showed that the meta-analytic OR for elevated
CRP in depressed patients compared with matched controls
was 1.51 (95% CI 1.22–1.88; p = 0.0002); see Supplementary
Table S1 and Fig. S20. A sensitivity analysis only including the
Fig. 3. Prevalence of elevated CRP (>1 mg/L) in depressed patients.
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nine studies that matched the patients and controls by BMI
showed that the meta-analytic OR for elevated CRP >1 mg/L in
depressed patients compared with matched controls was 1.52
(95% CI 1.12–2.07; p = 0.01); see Supplementary Fig. S21. A fur-
ther sensitivity analysis excluding studies where depression was
not active in all patients showed that the meta-analytic OR for ele-
vated CRP in depressed patients compared with healthy controls
was 1.47 (95% CI 1.19–1.81; p = 0.0003); see Supplementary
Fig. S22. Finally, a sensitivity analysis of the four studies excluding
subjects with very high levels of CRP (>10 mg/L) showed that the
meta-analytic OR for elevated CRP in depressed patients com-
pared with healthy controls was 1.29 (95% CI 0.38–4.30; p =
0.68); see Supplementary Fig. S23.
Very high CRP levels (>10 mg/L) in depressed patients and
healthy controls
We used data from four available studies comprising 3926
patients and 62 748 matched healthy controls. The meta-analytic
pooled prevalence of very high CRP in depressed patients
matched to healthy controls was 3% (95% CI 1–11%); in the
same studies, prevalence of very high CRP in healthy controls
matched to depressed patients was 1% (95% CI 0–4%); the
meta-analytic OR for very high CRP in depressed patients com-
pared with matched controls was 1.52 (95% CI 1.13–2.05; p =
0.006); see Supplementary Figs S24–26.
Discussion
To our knowledge, this is one of the first systematic reviews
and meta-analyses of the prevalence of low-grade inflammation
in patients with depression. We report that a notable pro-
portion of depressed patients show evidence of inflammation.
Approximately one in four patients with depression show CRP
levels >3 mg/L, a widely used threshold to define low-grade
inflammation in the literature. The prevalence is unaltered after
excluding poor quality studies, or after excluding studies where
depression was not active. After excluding patients with suspected
infection, the prevalence of low-grade inflammation is about one
in six. We also report that approximately three patients out of five
have mildly elevated CRP (>1 mg/L). The prevalence is unaltered
after excluding poor quality studies, or after excluding studies
where depression was not active. After excluding patients with
suspected infection, the prevalence of elevated CRP is one in
two. Meta-regression analyses show that the prevalence of inflam-
mation in depression is not associated with sex, age, BMI, ethni-
city or sample source.
Using matched non-depressed controls, we quantified the odds
ratios of low-grade inflammation and of elevated CRP in
depressed patients. We report that the proportion of patients
with depression showing elevated inflammatory markers as com-
pared to matched healthy controls is remarkably stable: the ORs
were 1.46 for CRP levels >3 mg/L, 1.47 for CRP levels >1 mg/L
and 1.52 for CRP levels >10 mg/L. There was no evidence of pub-
lication bias within the included studies, but there was evidence of
heterogeneity in all analyses.
Knowing inflammation levels in patients with depression
could be important for several reasons, particularly for predicting
the risk of physical illness and for predicting response to psychi-
atric treatment. Inflammation is a potentially causal risk factor for
CVD (Pearson et al., 2003), because CVD is associated with cir-
culating IL-6 and CRP levels (Pradhan et al., 2002; Danesh
Fig. 4. Odds ratio for elevated CRP (>1 mg/L) in depressed patients compared with matched controls.
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et al., 2004; Danesh et al., 2008) and with genetic variants regu-
lating levels/activity of IL-6 (IL6R Genetics Consortium
Emerging Risk Factors Collaboration, 2012; Interleukin-6
Receptor Mendelian Randomisation Analysis Consortium,
2012). Depression is co-morbid with CVD (Hare et al., 2013).
Depression increases the risk of incident CVD, and is a marker
of poor prognosis after myocardial infarction (Nicholson et al.,
2006). Inflammation could be a shared mechanism for these con-
ditions. Using Mendelian randomisation analysis of the UK
Biobank sample, we previously found that out of all cardiovascu-
lar risk factors, IL-6, CRP and triglycerides are likely to be causally
linked with depression (Khandaker et al., 2019). Therefore, car-
diovascular risk screening in depressed patients who show evi-
dence of inflammation could be useful. Our work suggests that
such screening will be relevant for about a quarter of patients
with depression.
We focussed on CRP levels as our preferred measure of
inflammation because it has been widely used in different fields
of medicine to measure inflammation, and standardised cut-offs
for CRP exist in the literature. The American Heart Association
and Center for Disease Control and Prevention have proposed
clear CRP thresholds as indicators of inflammation levels
(<1 = ‘low’, 1–3 = ‘medium’, >3 mg/L = ‘high’) (Pearson et al.,
2003). Our findings are consistent with previous meta-analyses
reporting higher mean concentrations of CRP, IL-6 and other
inflammatory markers in depressed patients compared with con-
trols (Howren et al., 2009; Dowlati et al., 2010; Haapakoski et al.,
2015; Goldsmith et al., 2016). Our study adds to the literature by
providing information on the proportion of depressed patients
who have evidence of inflammation.
In addition to depression and CVD, inflammation is asso-
ciated with other physical and psychiatric disorders including dia-
betes mellitus (Pradhan et al., 2001), schizophrenia (Miller et al.,
2011; Khandaker et al., 2015) and dementias (Schmidt et al.,
2002). Inflammation is also an important predictor of increased
all-cause mortality (Zacho et al., 2010; Sung et al., 2014; Li
et al., 2017). Therefore, routine CRP screening in patients with
depression, and identification and treatment of the cause of
inflammation could improve overall health-related mortality and
morbidity. Public health interventions aimed at reducing inflam-
mation could improve mortality and morbidity associated with a
number of conditions.
It is unlikely that anti-inflammatory drugs will be useful for all
patients with depression (Khandaker et al., 2017). Measurement
of CRP levels could inform patient selection in RCTs of anti-
inflammatory drugs for depression. We are aware of two studies
that are testing novel anti-inflammatory drugs such as monoclo-
nal antibodies (mAb) against the IL-6/IL-6R pathway. One study
testing the efficacy and safety of sirukumab (anti-IL-6 mAb) for
depression has completed recruitment (NCT02473289). We are
conducting an RCT of tocilizumab (anti-IL-6R mAb) for patients
with depression (Khandaker et al., 2018). Both of these studies are
based on patients with CRP levels ⩾3 mg/L. Secondary analysis of
existing RCTs suggests mAb against specific inflammatory cyto-
kines, such as IL-6/IL-6R, could be helpful for depression (Sun
et al., 2017; Kappelmann et al., 2018). However, definitive efficacy
trials need to be completed before anti-inflammatory drugs can be
considered in psychiatric clinical practice. Our findings suggest
that up to a quarter of depressed patients show signs of low-grade
inflammation. Future studies should explore the potential causes
for this, and also whether depressed patients with higher CRP
levels may benefit from anti-inflammatory treatments.
Studies included in this review varied on setting, country and
analytic methods, and the proportion of depressed patients with
elevated CRP (>3 mg/L) in these studies ranged between 0%
and 60%. In our analyses, the prevalence of inflammation was
not associated with participant age and sex, antidepressant treat-
ment, ethnicity or source of sample. This is the case despite the
samples spanning all age groups [median age: 42.2 years; inter-
quartile range (IQR): 37–59]. Both sexes were well represented
(median proportion of males: 36%, IQR: 17–41%). The samples
comprised both antidepressant-free and treated populations
(antidepressant-free = 6 studies; 100% treated = 3 studies; mixed
populations = 10 studies). Included studies covered samples col-
lected from inpatient (N = 6), outpatient (N = 15) and general
population (N = 9). One reason for not detecting an association
between inflammation and sociodemographic factors could be
that a number of studies matched patients and controls on
these factors.
The meta-analytic prevalence of low-grade inflammation (CRP
>3 mg/L) in non-depressed controls seen in our analysis is 16%,
which is lower than the prevalence of inflammation reported in
some general population studies. For instance, Ford et al. (2004)
reported the prevalence of low-grade inflammation to be about
25% in a sample of adult US women. Khera et al. (2005) reported
the prevalence of CRP >3 mg/L to be >30% in US adult males and
females. One reason for these high prevalence reports in general
population samples could be that these studies include both
healthy and diseased individuals including those with chronic
inflammatory physical illness. Therefore, for a more accurate
comparison of the prevalence of inflammation between depressed
cases and healthy controls, we have used studies that included
cases matched to healthy controls for the calculation of odds
ratios. In our results, the stability of the odds ratios for elevated
CRP in depressed patients compared with healthy controls across
different CRP thresholds (ORs = 1.46 for CRP levels >3 mg/L; OR
= 1.47 for CRP levels >1 mg/L; and OR = 1.52 for CRP levels
>10 mg/L) provides confidence that patients are more likely to
have evidence of inflammation than healthy controls.
Furthermore, excluding patients with very high levels of inflam-
mation did not significantly affect the odds ratio for low-grade
inflammation (>3 mg/L) in depressed subjects (OR = 1.44).
Strengths of this work include the systematic nature of the lit-
erature search, which identified a large number of relevant studies
comprising 13 541 patients and 155 728 controls from different
countries and settings, and spanning diverse ethnic and age
groups. The methods were laid out prospectively and published
on PROSPERO (Osimo et al., 2018a). We assessed the studies
for quality using the validated Newcastle–Ottawa Scale (Stang,
2010). We conducted multiple sensitivity analyses to examine
the robustness of the findings. There was no evidence of publica-
tion bias, suggesting that we covered a range of results spanning
the whole expected distribution of means.
Limitations of this work include sample heterogeneity: the
studies we included used different methods to assess depression
(albeit a valid method was required for inclusion), and samples
were recruited from different sources making it difficult to test
the association between the prevalence of inflammation and
depression severity. However, we have reported meta-analytic
results separately by sample source (community, inpatient, etc.),
which could be taken as an indirect indicator of depression sever-
ity. Inflammation prevalence did not differ much by sample
source. However, due to the lack of comparable data on depres-
sion severity, we could not assess this directly. Study setting and
10 Emanuele Felice Osimo et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291719001454
Downloaded from https://www.cambridge.org/core. UCL, Institute of Education, on 08 Jul 2019 at 14:32:27, subject to the Cambridge Core terms of use, available at
sample characteristics could account for some of the observed
heterogeneity. We used random-effects meta-analyses in order
to take care of inter-study variability. Another limitation is that
we were not able to account for comorbidities, partly because
for some studies this information was not reported. By design
we have focused on dichotomous measure of inflammation, so
we cannot comment on the distributions of continuous CRP
values in patients/controls; these have been subject to previous
meta-analyses reporting higher mean levels of CRP in depression
compared with controls (Howren et al., 2009; Dowlati et al., 2010;
Haapakoski et al., 2015; Goldsmith et al., 2016).
In summary, this systematic review and meta-analysis provides
a robust estimate of the prevalence of low-grade inflammation in
depressed patients, which is about one in four. We also report that
depressed patients are about 50% more likely to have evidence of
inflammation as compared to matched non-depressed controls.
These findings are relevant for future treatment studies of anti-
inflammatory drugs and for clinical practice, particularly for pre-
dicting response to antidepressants and for predicting co-morbid,
immune-related physical illness, such as CVD.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291719001454
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